Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446500 | 1.00 | POLB (0.39) | POLBF9F10L3MBTL1RXFP1 | |
| SCHEMBL19196317 | 0.92 | RAB9A (0.38) | F9F10L3MBTL1LMNARAB9A | |
| SCHEMBL19180638 | 0.90 | POLB (0.45) | POLBF9F10L3MBTL1LMNA | |
| SCHEMBL17336849 | 0.83 | POLB (0.44) | POLBRXFP1LMNARAB9AHPGD | |
| SCHEMBL29446493 | 0.83 | POLB (0.44) | POLBRXFP1LMNARAB9AHPGD | |
| SCHEMBL6434623 | 0.83 | NOTUM (0.39) | POLBL3MBTL1KMT2A | |
| SCHEMBL6434059 | 0.83 | POLB (0.37) | POLBL3MBTL1RXFP1LMNAALDH1A1 | |
| SCHEMBL6433115 | 0.82 | ABL1 (0.45) | POLBF9F10L3MBTL1 | |
| SCHEMBL2320083 | 0.81 | POLB (0.43) | POLBRXFP1LMNARAB9AHPGD | |
| SCHEMBL29446511 | 0.81 | POLB (0.43) | POLBRXFP1LMNARAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154954-B1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20200347021-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2020-11-05 | — | — | US | disclosed |
| US-10597367-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190016715-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-17 | — | — | US | disclosed |
| US-9969726-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-08-03 | — | — | US | disclosed |
| WO-2015191630-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347021-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | POLB 3950/4885F9 4800/4885F10 4836/4885 |
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | GRM3, GRM2, GRM1 | POLB 3950/4885F9 4800/4885F10 4836/4885 |
| US-20190016715-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | POLB 3950/4885F9 4800/4885F10 4836/4885 |
| US-10597367-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | POLB 3950/4885F9 4800/4885F10 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.